Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cylexin for Prevention of Reperfusion Injury in Neonates/Infants Undergoing Hypothermic CPB
NCT00226369Phase 3Completed
- Sponsor
- Boston Children's Hospital
- Start
- Dec 1997
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in reperfusion injury (IRI) comparing Cylexin with Placebo (2 arms). Primary endpoints: Non-operative mortality within 30 days, Time from ICU admission to extubation and 3 more. Started Dec 1997; status: completed.
02
Drugs
CY-1503
03
Conditions
reperfusion injury (IRI)
Beyond the preview
Go deeper on NCT00226369.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00226369.